Cancer Breakthroughs - Dr. William Makis

Segment #680

This past year I watched my younger brother die from pancreatic cancer and the constant barrage of chemotherapy that destroyed his immune system. It was all about the money and expensive treatments that have a poor track record. Cancer is a huge business. You can’t hand over the responsibility for your health to the medical complex that does not have your best interest as a priority

Innovative Cancer Treatments That Are Game-Changers - Dr. William Makis Interview

Find this on Rumble - Innovative Cancer Treatments That Are Game-Changers - Dr. William Makis Interview. Makis has been persecuted by Trudeauc and the Canadian government

Who is Dr. William Makis?

Dr. William Makis is a Canadian physician and radiologist, formerly affiliated with Alberta Health Services and the Cross Cancer Institute in Edmonton. He holds an MD from McGill University and has authored over 100 peer-reviewed publications in nuclear medicine, radiology, and oncology. Makis has gained prominence (and controversy) for advocating the off-label use of antiparasitic drugs like ivermectin and fenbendazole (often misspelled as "Febendazole") in cancer treatment. He runs what he describes as the world's largest online ivermectin cancer clinic, claiming to have helped over 7,000 patients since mid-2024 through personalized protocols shared via his Substack newsletter and X (formerly Twitter) account (

@MakisMedicine

). His work focuses on "repurposed drugs" and "turbo cancers"—a term he uses for aggressive, rapidly progressing cancers, which he links to COVID-19 vaccines (a claim lacking broad scientific consensus).Makis emphasizes a "hybrid orthomolecular" approach, combining these drugs with nutraceuticals (e.g., curcumin, CBD oil) and conventional therapies (e.g., chemotherapy) to target cancer stem cells, disrupt tumor metabolism, and induce apoptosis (cell death). He reports response rates of up to 75% across cancers when combining ivermectin and fenbendazole, based on patient testimonials and preclinical data. However, his protocols are not approved by regulatory bodies like the FDA or Health Canada for cancer, and he faces professional scrutiny, including investigations by the College of Physicians and Surgeons of Alberta.Ivermectin and Fenbendazole in Cancer: Makis' PerspectiveMakis promotes ivermectin (an FDA-approved antiparasitic for humans) and fenbendazole (a veterinary dewormer, similar to human-use mebendazole) as low-cost, accessible options with multiple anti-cancer mechanisms. He argues they outperform or complement expensive therapies, citing:

• Ivermectin: Inhibits cancer stem cells, induces mitochondrial dysfunction, and promotes autophagy/apoptosis. Doses: 1 mg/kg/day (high-dose for cancer).

• Fenbendazole/Mebendazole: Blocks microtubule formation, starves tumors by inhibiting glucose/glutamine uptake, and activates p53 (a tumor suppressor). Doses: 222–1,000 mg/day, often 3 days on/4 off.

• Combination: Synergistic effects, e.g., with immunotherapy like Keytruda, leading to tumor shrinkage and remission in testimonials.

He shares protocols via Substack, categorizing by cancer stage/grade:

Cancer Grade/Stage

Ivermectin Dose

Fenbendazole/Mebendazole Dose

Additional Notes

Low-grade/Stage 1–2

0.2–0.4 mg/kg/day

222 mg, 3x/week

+ Vitamin E (800 IU), Curcumin (600 mg), CBD (25 mg) daily

Intermediate/Stage 3

0.6–0.8 mg/kg/day

444 mg/day

Monitor liver enzymes; combine with low-carb diet

High-grade/Stage 4

1 mg/kg/day

888–1,000 mg/day

+ Methylene blue or castor oil packs; synergize with chemo

These are not medical advice but summaries from his publications. Makis stresses consulting physicians and monitoring via scans/bloodwork (e.g., CEA levels).Key Publications by Makis

• 2024: "Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol" (International Journal of Orthomolecular Medicine, co-authored with Paul Marik et al.). Reviews preclinical evidence for ivermectin, mebendazole, and fenbendazole in disrupting cancer metabolism and stem cells. Claims synergy with dichloroacetate and omeprazole.

• 2025: "Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients" (Case Reports in Oncology). Documents tumor regression in three self-treated patients using fenbendazole.

Over 400 studies support antiparasitics' potential (e.g., ivermectin in breast/colon cancer models), but most are preclinical (lab/animal).Patient Testimonials and Reported OutcomesMakis posts frequent X updates with anonymized cases, often showing CT/PET scan improvements or remissions. Examples from 2025:

• Stage 4 Pancreatic Cancer (57-year-old man, California): After 4 months of ivermectin + fenbendazole, tumors shrank dramatically; CEA dropped from 1,200 to 2.9.

• Stage 4 Colon Cancer (51-year-old man, UK): 2.5 months on ivermectin + fenbendazole + immunotherapy; oncologist noted "struggled to see cancer on scan."

• Stage 4 Breast Cancer (53-year-old woman, UK): 2 months on low-dose ivermectin + high-dose fenbendazole; breast mass volume reduced 68%.

• Diffuse Large B-Cell Lymphoma (Farmer, unspecified location): Achieved "cancer-free" status using ivermectin + fenbendazole in "secret smoothies" to evade hospital staff.

• Two Blood Cancers (AML/CLL patients): One became "cancer-free"; the other improved for the first time in 2 years.

He claims 100,000+ people worldwide now use these combos, with hundreds of testimonials. High-profile mentions include actor Mel Gibson on the Joe Rogan podcast (January 2025), crediting them for three friends' stage 4 remissions—possibly Makis' patients.Scientific Evidence and CriticismsSupporting Data:

• Preclinical studies (e.g., 2022 review in Cancers journal) show benzimidazoles like fenbendazole disrupt microtubules and glucose uptake in cancer cells.

• Case series (e.g., 2021 Stanford report) note tumor enhancement with fenbendazole.

• Makis' 2025 PubMed series reports remission in self-administered cases.

Limitations and Skepticism:

• No large-scale, randomized human trials exist for these drugs in cancer. Evidence relies on anecdotes, case reports, and lab studies—not sufficient for efficacy claims.

• Fact-checks (e.g., Science Feedback, AFP) label Makis' protocol as "inadequate support," warning it may delay proven treatments, risking progression. The Canadian Cancer Society states: "These are being studied, but more research is needed... risks include cancer spreading."

• Side effects: Ivermectin overdose can cause nausea, seizures; fenbendazole lacks human safety data at high doses.

• Bias concerns: Makis' work appears in orthomolecular journals (fringe to mainstream oncology) and ties to anti-vaccine narratives. Reddit threads question his claims as "potential scams," though some report personal successes.

Regulatory bodies (FDA, EMA) approve these only for parasites, not cancer. Oncologists like those at Mayo Clinic or MD Anderson do not recommend them.Broader Context and RecommendationsMakis frames this as a "revolution" against Big Pharma's "trillion-dollar cartel," citing suppressed trials due to low profitability. He's planning a physical clinic in Florida (e.g., near Mayo Jacksonville) for easier access. Public figures like Joe Rogan amplify his reach.Important Disclaimer: This is not medical advice. Cancer treatment should involve licensed oncologists. Self-administration risks harm; consult professionals before off-label use. For balanced views, review sources like PubMed or oncology guidelines.For more, follow Makis on X (

@MakisMedicine

) or his Substack (makismd.substack.com). If seeking protocols, he offers paid consultations via his site. Ongoing research may clarify these drugs' role—stay informed via clinicaltrials.gov.